Ryan Nipp to Antineoplastic Agents
This is a "connection" page, showing publications Ryan Nipp has written about Antineoplastic Agents.
Connection Strength
1.780
-
Oncology drug pricing: potential Medicare savings on cancer-directed and supportive care medications through the Mark Cuban cost plus drug model. Oncologist. 2024 Jul 05; 29(7):e918-e921.
Score: 0.622
-
A coming of age for immune checkpoint inhibitors in cancer. Immunotherapy. 2019 06; 11(8):647-650.
Score: 0.437
-
Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms. JCO Oncol Pract. 2022 02; 18(2):140-147.
Score: 0.128
-
Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin. Oncologist. 2021 04; 26(4):325-331.
Score: 0.122
-
Health care-related time costs in patients with metastatic breast cancer. Cancer Med. 2020 11; 9(22):8423-8431.
Score: 0.120
-
Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clin Cancer Res. 2020 04 15; 26(8):1877-1885.
Score: 0.114
-
Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Ann Surg. 2019 04; 269(4):733-740.
Score: 0.108
-
Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Oncologist. 2019 07; 24(7):945-954.
Score: 0.106
-
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. Oncologist. 2017 08; 22(8):963-971.
Score: 0.024